Opportunity overview
Award notice for the above CDMO services tender. Previous description as follows - The School of Medicine successfully applied for a UKRI grant to investigate in a randomised controlled trial (RCT), a new IMP (investigational medicinal product) called Triiodothyronine sulphate (T3S) in hypothyroid subjects with a gene difference in a thyroid related enzyme called deiodinase 2 (D2). We are looking for a CDMO to (i) Import and QP sign off T3S and matched placebo tablets obtained from Ardena, Pamplona, Spain who will manufacture these to GMP standards; (ii) over encapsulate commercially secured L-thyroxine (LT4 ) and matched placebo capsules; (iii) store T3S and matched placebo obtained from Ardena, and over encapsulated LT4 and matched placebo; (iv) label T3S, LT4 and respective placebo packs for distribution to trial subjects; (v) distribute T3S and matched placebo and over encapsulated LT4 and matched placebo packs to trial pharmacy (Royal Glamorgan Hospital, Wales).
Awarded to
Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.
Simbec-Orion Group Ltd
- Published award value
- £212.5k
- Awarded
- 10 Sept 2026
- Award ID
- 1
- Status
- pending
- Identifier
- GB-PPON PXYC-8233-ZDGQ
- Location
- Pentre Bach, Merthyr Tydfil, UKL15, CF48 4DR, United Kingdom
Classification
No classification was supplied.
Lots
- Lot 1Value not stated
Documents and notices
- Contract award notice on Find a TenderOpen source ↗